VYOME HOLDINGS INC (HIND)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$2.22-0.45%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · HIND
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance recently climbed back into the top half of its industry — confirming the recovery.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 46.6% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| -60.0% |
Growth built into the price is above our model estimate.
The price assumes 106.6 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
HIND — CEO transition
Dated 2026-08-28
CFO — Jerry Leonard: The filing discloses the appointment of an external fractional CFO, which is a new hire rather than a departure of a sitting executive.
Why it matters: Advancing VT-1953 is important for Vyome's growth. It could open up big market chances.
Supportive ifManagement says they finished key steps for VT-1953.
Worry ifManagement says there are delays in moving VT-1953 to the next stage.
Why it matters: This acquisition is key for growth. Delays could hurt future plans.
Supportive ifA press release confirming the acquisition is completed or on track.
Worry ifThere are no updates or delays in the acquisition process.
Why it matters: Positive FDA feedback could speed up the development of VT-1953 for a serious condition.
Supportive ifFDA gives good feedback on VT-1953 plans and submissions.
Worry ifFDA has big concerns about VT-1953 plans or rejects the submissions.
Why it matters: Getting this designation can help with market exclusivity and incentives. These are important for the drug's success.
Supportive ifFDA grants Orphan Drug Designation for VT-1953.
Worry ifFDA denies Orphan Drug Designation for VT-1953.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$175 on $10,000 · ±1.8% | How much price usually moves either way. |
| Bad day | $757 loss on $10,000 · 7.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,664 loss on $10,000 · 76.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Fixing lawsuit problems could help the company run better and grow.
Supportive ifA court ruling or settlement that favors Vyome Holdings.
Worry ifNew lawsuits come up or current cases get worse.
Why it matters: Earnings results will show the company's financial health and progress. This matters for future growth.
Watch forQ2 earnings show better revenue or smaller losses than Q1.
Also watch forQ2 earnings show ongoing losses or lower revenue.
Why it matters: Feedback from the FDA will guide the next steps for the VT-1953 program. This is crucial for advancing the treatment for malignant fungating wounds.
Supportive ifThe FDA gave positive feedback on the study plan for VT-1953.
Worry ifNegative feedback from the FDA that delays or alters the pivotal study strategy for VT-1953.
Why it matters: A big drop in cash could hurt Vyome's ability to fund projects.
Worry ifCash and cash equivalents are below $7 million in the next report.
Less concerning ifCash and cash equivalents are over $7 million. This shows financial strength.
Why it matters: Progress on these projects may lead to new ways to make money. This is important for treating autoimmune and inflammatory diseases.
Watch forThere will be news about clinical trials or key steps for the JAK inhibitor projects.
Also watch forThere are no updates on the JAK inhibitor projects or there are delays in development.
Why it matters: Solving legal issues can help the company and lower risks.
Supportive ifA public statement shows progress or a solution to legal issues.
Worry ifThere are new legal changes. No progress has been reported.